I agree that this site is using cookies. You can find further informations here.
X
Delea, Thomas E.
127  results:
Search for persons X
?
1

Hemoglobin and End-Organ Damage in Individuals with Sickle ..:

Ershler, William B. ; De Castro, Laura M. ; Pakbaz, Zahra...
Current Therapeutic Research.  98 (2023)  - p. 100696 , 2023
Link: https://doi.org/10.1016/..
 
?
2

Quality-Adjusted Survival with Ribociclib Plus Fulvestrant ..:

Jerusalem, Guy ; Delea, Thomas E. ; Martin, Migule...
Clinical Breast Cancer.  22 (2022)  4 - p. 326-335 , 2022
Link: https://doi.org/10.1016/..
 
?
3

Cost Effectiveness of Ribociclib in Combination with Fulves..:

Stellato, Daniel ; Thabane, Marroon E. ; Park, Jinhee..
PharmacoEconomics.  39 (2021)  9 - p. 1045-1058 , 2021
Link: https://doi.org/10.1007/..
 
?
4

Lifetime Costs for Treated Follicular Lymphoma Patients in ..:

Eichten, Caitlin ; Ma, Qiufei ; Delea, Thomas E....
PharmacoEconomics.  39 (2021)  10 - p. 1163-1183 , 2021
Link: https://doi.org/10.1007/..
 
?
5

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fu..:

Fasching, Peter A ; Delea, Thomas E ; Lu, Yen-Shen...
Cancer Management and Research.  13 (2021)  - p. 8179-8189 , 2021
Link: https://doi.org/10.2147/..
 
?
6

Preferences of Canadian Patients and Physicians for Treatme..:

Stellato, Daniel ; Thabane, Marroon ; Eichten, Caitlin.
Current Oncology.  28 (2021)  1 - p. 491-508 , 2021
Link: https://doi.org/10.3390/..
 
?
7

Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromat..:

Stellato, Daniel ; Thabane, Marroon E. ; Chandiwana, David..
PharmacoEconomics.  39 (2021)  7 - p. 853-867 , 2021
Link: https://doi.org/10.1007/..
 
?
8

Real-World Treatment Patterns, Healthcare Use and Costs in ..:

Madduri, Deepu ; Hagiwara, May ; Parikh, Kejal...
Future Oncology.  17 (2020)  5 - p. 503-515 , 2020
Link: https://doi.org/10.2217/..
 
?
9

Preferences of Canadian Patients and Physicians for Adjuvan..:

Stellato, D. ; Thabane, M. ; Eichten, C..
Current Oncology.  26 (2019)  6 - p. 755-765 , 2019
Link: https://doi.org/10.3747/..
 
?
10

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogam..:

Delea, Thomas E. ; Zhang, Xinke ; Amdahl, Jordan...
PharmacoEconomics.  37 (2019)  9 - p. 1177-1193 , 2019
Link: https://doi.org/10.1007/..
 
?
11

Cost-effectiveness of dabrafenib and trametinib in combinat..:

Gerbasi, Margaret E. ; Stellato, Daniel ; Ghate, Sameer R....
Journal of Medical Economics.  22 (2019)  12 - p. 1243-1252 , 2019
Link: https://doi.org/10.1080/..
 
?
12

Cost-Effectiveness of Thoracic Radiation Therapy for Extens..:

Patrice, Grace I. ; Lester-Coll, Nataniel H. ; Yu, James B....
International Journal of Radiation Oncology*Biology*Physics.  100 (2018)  1 - p. 97-106 , 2018
Link: https://doi.org/10.1016/..
 
?
13

Budget Impact Analysis of PCSK9 Inhibitors for the Manageme..:

Mallya, Usha G. ; Boklage, Susan H. ; Koren, Andrew..
PharmacoEconomics.  36 (2017)  1 - p. 115-126 , 2017
Link: https://doi.org/10.1007/..
 
?
14

Estimating outcomes and cost effectiveness using a single-a..:

Hatswell, Anthony J. ; Thompson, Gwilym J. ; Maroudas, Penny A...
Cost Effectiveness and Resource Allocation.  15 (2017)  1 - p. , 2017
Link: https://doi.org/10.1186/..
 
?
15

Survival Outcomes in Patients With Chronic-Phase Chronic My..:

Stellato, Daniel R. ; McGarry, Lisa ; Huang, Hui...
Clinical Lymphoma Myeloma and Leukemia.  17 (2017)  - p. S311-S312 , 2017
Link: https://doi.org/10.1016/..
 
1-15